Conditions: Asthma
Keywords: Asthma patients lung function
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 39
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of single doses of three different dry powder inhalation formulations of AZD3199 administered via Single Inhalation Device (SID) compared to AZD3199 administered via Turbuhaler™ Inhaler and compared to placebo in patients with persistent asthma.

Detailed description:

Arms:
arm 1: AZD3199 800 µg inhaled via single inhaler device (SID), single dose arm 2: AZD3199 880 µg inhaled via SID, single dose arm 3: AZD3199 1400 µg inhaled via SID, single dose arm 4: AZD3199 300 µg inhaled via Turbuhaler inhaler, single dose arm 5: AZD3199 1200 µg inhaled via Turbuhaler inhaler, single dose arm 6: Placebo inhaled via Turbuhaler inhaler and SID, single dose

Interventions: intervention 1: AZD3199 intervention 2: AZD3199 intervention 3: AZD3199 Placebo
Intervention descriptions: intervention 1: Inhaled via single inhaler device (SID) intervention 2: Inhaled via Turbuhaler inhaler intervention 3: Inhaled via Turbuhaler inhaler and SID

Protocol document: